Bristol Myers Squibb Company $BMY Shares Bought by Kinsale Capital Group Inc.

Kinsale Capital Group Inc. grew its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 12.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 168,640 shares of the biopharmaceutical company’s stock after purchasing an additional 18,863 shares during the period. Kinsale Capital Group Inc.’s holdings in Bristol Myers Squibb were worth $7,606,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the company. Gateway Investment Advisers LLC grew its stake in shares of Bristol Myers Squibb by 10.0% during the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after acquiring an additional 10,284 shares in the last quarter. CWA Asset Management Group LLC grew its position in shares of Bristol Myers Squibb by 25.9% during the 3rd quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after buying an additional 30,909 shares during the last quarter. Commonwealth Retirement Investments LLC increased its position in Bristol Myers Squibb by 24.6% in the second quarter. Commonwealth Retirement Investments LLC now owns 59,183 shares of the biopharmaceutical company’s stock worth $2,740,000 after buying an additional 11,690 shares during the period. Railway Pension Investments Ltd increased its position in Bristol Myers Squibb by 3.7% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock valued at $51,396,000 after acquiring an additional 40,300 shares during the period. Finally, Stephens Inc. AR increased its stake in shares of Bristol Myers Squibb by 13.5% during the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after acquiring an additional 32,476 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Q4 revenue beat and growth portfolio momentum — BMY reported $12.5B in Q4 revenue with growth in new products (immuno‑oncology) helping offset legacy declines; investors view the topline beat as validating the company’s transition. Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
• Positive Sentiment: Upside FY‑2026 guidance — management set FY‑2026 EPS of $6.05–$6.35 and revenue guidance of $46.0–$47.5B, both above consensus, which markets are treating as a material bullish catalyst for forward earnings and cash flow expectations. Bristol Myers forecasts upbeat 2026, expecting Eliquis price cut to pay off
• Positive Sentiment: Management and pipeline commentary — CEO Chris Boerner highlighted the strongest pipeline in a decade and called out new growth engines, supporting investor confidence in sustained medium‑term revenue growth. Bristol Myers Squibb CEO: Richest product pipeline we’ve had in the last decade
• Positive Sentiment: Street reaction — Citigroup raised its price target from $60 to $64 (maintaining a neutral rating), signalling modest analyst support for upside after the print and guidance. Tickerreport: Citigroup raises target
• Neutral Sentiment: Dividend/total-return thesis discussed — commentary (Seeking Alpha) frames BMY as a dividend income play with hidden upside from pipeline and buybacks; relevant for income-oriented investors but less immediate as a price catalyst. Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026
• Negative Sentiment: EPS mix and legacy headwinds — non‑GAAP EPS dynamics and year‑over‑year decline in EPS (and some legacy drug declines) remain a risk; some outlets note EPS was below certain Street figures and that company sales may decline in 2026 before new-product gains fully offset legacy erosion. MarketBeat: Earnings and call materials
• Negative Sentiment: Some analysts/publication notes that overall sales could decline in 2026 — this has been flagged as a medium‑term headwind that could pressure consensus if new-product uptake lags expectations. MSN: Bristol Myers expects sales to decline this year

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on BMY shares. Truist Financial set a $65.00 target price on Bristol Myers Squibb in a report on Wednesday, December 3rd. Citigroup raised their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday. Leerink Partners boosted their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Finally, Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Eight analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Bristol Myers Squibb has a consensus rating of “Hold” and an average target price of $59.20.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $61.99 on Friday. The company has a market capitalization of $126.20 billion, a P/E ratio of 17.97, a P/E/G ratio of 0.19 and a beta of 0.29. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $63.33. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. The firm has a 50-day moving average price of $54.34 and a two-hundred day moving average price of $49.03.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 70.30%. The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter in the previous year, the business posted $1.67 earnings per share. The company’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd were given a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, January 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.1%. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is 73.04%.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.